Evidence map›Paper›PMID 30288571›Full record

ArticleDiabetologia2018

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse

Erratum issued Registry-linked trialOpen access · bronzeAbstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04295031 (AMEMET Study - Observational Multicentric Clinical Study), which is not on this map. Cited by 476 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
476citing papers in PubMed, 16 pooled it
160.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04295031 unknown statusnot on this mapstarted 2019, after this paper: background citation

AMEMET Study - Observational Multicentric Clinical Study: Metformin in Patients Over 65 Years With Type 2 Diabetes (DM2)

TypeobservationalSponsorAssociazione Medici EndocrinologiRan2019 to 2021Enrolled1,500ConditionsDiabetes Mellitus, Type 2
3 · Its place in the literature

Who cites it

476 citing papers in PubMed, 16 syntheses or guidelines pooled it, 1,460 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Trial
  18. Trial
  19. Trial
  20. Trial

416 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 6 countries.

Melanie J DaviesDiabetes Research Centre, University of Leicester, Leicester, UK. Melanie.davies@uhl-tr.nhs.uk.
David A D'AlessioDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Judith FradkinNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Walter N KernanDepartment of Medicine, Yale School of Medicine, New Haven, CT, USA.
Chantal MathieuClinical and Experimental Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium.
Geltrude MingroneDepartment of Internal Medicine, Catholic University, Rome, Italy.
Peter RossingSteno Diabetes Center Copenhagen, Gentofte, Denmark.
Apostolos TsapasSecond Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece.
Deborah J WexlerDepartment of Medicine and Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA.
John B BuseDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Aristotle University of Thessaloniki · GRDuke University · USKing's College London · GBKU Leuven · BEMassachusetts General Hospital · USNational Institutes of Health · USSteno Diabetes Center · DKUniversity of Leicester · GBUniversity of North Carolina at Chapel Hill · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2EuropeGlucagon-Like Peptide-1 Receptor AgonistsHeart FailureHumansHyperglycemiaHypoglycemic AgentsInsulinLiraglutideRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsUnited StatesGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulinLiraglutideSodium-Glucose Transporter 2 InhibitorsCardiovascular diseaseChronic kidney diseaseCostsGlucose-lowering therapyGuidelinesHeart failureHypoglycaemiaPatient-centred careType 2 diabetes mellitusWeight management

Identifiers

PMID30288571
OpenAlexW2895533920

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.